Forsham v. Harris

445 U.S. 169, 100 S. Ct. 977, 63 L. Ed. 2d 293, 1980 U.S. LEXIS 27, 5 Media L. Rep. (BNA) 2473
CourtSupreme Court of the United States
DecidedMarch 3, 1980
Docket78-1118
StatusPublished
Cited by276 cases

This text of 445 U.S. 169 (Forsham v. Harris) is published on Counsel Stack Legal Research, covering Supreme Court of the United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Forsham v. Harris, 445 U.S. 169, 100 S. Ct. 977, 63 L. Ed. 2d 293, 1980 U.S. LEXIS 27, 5 Media L. Rep. (BNA) 2473 (1980).

Opinion

Mr. Justice Rehnqtjist

delivered the opinion of the, Court.

The Freedom of Information Act, 5 U. S. C. § 552, empowers federal courts to order an “agency”, to produce “agency records improperly withheld” from an individual requesting access. § 552 (a)(4)(B). We hold here that written data generated, owned, and possessed by a privately controlled organization receiving federal study grants aré not “agency records” within the meaning of the Act when copies of those data have not been obtained by a federal agency subject to the FOIA. Federal participation in the generation of the data by means of a grant from the Department of Health, Education, and Welfare. (HEW) does not make the private organization a federal “agency” within the terms of the Act. Nor does this federal funding in combination with a federal right of access render the data “agency records” of HEW, which is a federal “agency” under the terms of the Act.

I

In 1959, a group of private physicians and scientists specializing in the treatment of diabetes formed the University Group Diabetes Program (UGDP). The UGDP conducted a long-term study of the effectiveness of five diabetes treatment regimens. Two of these treatment regimens involved diet control in combination with the administration of either tolbutamide, or phenformin hydrochloride, both “oral hypoglycemic” drugs. The UGDP’s participating physicians were located at 12 clinics nationwide and the study was coordinated at the Coordinating Center of the University of Maryland.

*172 The study generated more than 55 million records documenting the treatment of over 1,000 diabetic patients who were monitored for a 5- to 8-year period. In 1970, the TJGDP presented the initial results of its study indicating that the treatment of adult-onset diabetics with tolbutamide increased the risk of death from cardiovascular disease over that present when diabetes was treated by the other methods studied. The TJGDP later expanded these findings to report a similarly increased incidence of heart disease when patients were treated with phenformin hydrochloride. These findings have in turn generated substantial professional debate.

The Committee on the Care of the Diabetic (CCD), a national association of physicians involved in the treatment of diabetes mellitus patients, have been among those critical of the TJGDP study. CCD requested the TJGDP to grant it access to the raw data in order to facilitate its review of the TJGDP findings, but TJGDP has declined to comply with that request. CCD therefore sought to obtain the information under the Freedom of Information Act. The essential facts are not in dispute, and we hereafter set forth those relevant to our decision.

The TJGDP study has been solely funded by federal grants in the neighborhood of $15 million between 1961 and 1978. These grants were awarded TJGDP by the National Institute of Arthritis, Metabolism, and Digestive Diseases (NIAMDD), a federal agency, 1 pursuant to the Public Health Service Act, 42 U. S. C. § 241 (c). NIAMDD has not only awarded the federal grants to TJGDP, but has exercised a certain amount *173 of supervision over the funded activity. Federal regulations governing supervision of grantees allow for the review of periodic reports submitted by the grantee and on-site visits, and require agency approval of major program or budgetary changes. 45 CFR §§ 74.80-74.85 (1979); 42 CFR § 52.20 (b) (1979). It is undisputed, however, both that the day-to-day administration of grant-supported activities is in the hands of a grantee, and that NIAMDD’s supervision of UGDP conformed to these regulations. 2

The grantee has also retained control of its records: the patient records and raw data generated by UGDP have at all times remained in the possession of that entity, and neither the NIAMDD grants nor related regulations shift ownership of such data to the Federal Government. NIAMDD does, however, have a right of access to the data in order to insure compliance with the grant. 45 CFR § 74.24 (a) (1979). And the Government may obtain permanent custody of the documents upon request. § 74.21 (c). But NIAMDD has not exercised its right either to review or to obtain permanent custody of the data.

Although no employees of the NIAMDD have reviewed the UGDP records, the Institute did contract in 1972 with another private grantee, the Biometric Society, for an assessment of the validity of the UGDP study. The Biometric Society was given direct access to the UGDP raw data by the terms of its contract with NIAMDD. The contract with the Biometric Society, however, did not require the Society to seek access to the UGDP raw data, nor did it require that any data actually reviewed be transmitted to the NIAMDD. While the Society did review some UGDP data, it did not submit any raw data reviewed by it to the NIAMDD. The Society *174 issued a report to the Institute in 1974 concluding that the UGDP results were “mixed” but “moderately strong.”

An additional connection between the Federal Government and the UGDP study has occurred through the activities of the Food and Drug Administration. After the FDA was apprised of the UGDP results, the agency issued a statement recommending that physicians use tolbutamide in the treatment of diabetes only in limited circumstances. After the UGDP reported finding a similarly higher incidence of cardiovascular disease with the administration of phenformin, the FDA proposed changes in the labeling of these oral hypoglycemic drugs to warn patients of cardiovascular hazards. FDA Drug Bulletin (June 23, 1971). The FDA deferred further action on this labeling proposal, however, until the Biometric Society completed its review of the UGDP study. 3

After the Biometric study was issued, FDA renewed its proposal to require a label warning that oral hypoglyeemics should be used only in cases of adult-onset, stable diabetes that could not be treated adequately by a combination of diet and insulin. The FDA clearly relied on the UGDP study in renewing this position. 40 Fed. Reg. 28587, 28591 (1975). At the time the proposal was published, the FDA invited public comment. In response to criticism of the UGDP study and the Biometric Society’s audit, the FDA conducted its own audit of the UGDP study pursuant to a delegation of NIAMDD’s authority to audit grantee records. In conducting this audit, the FDA examined and copied a small sample of the UGDP raw data. This audit report has been made available for public inspection. 43 Fed. Reg. 52733 (1978).

Although this labeling proposal has not yet become final, other FDA regulatory action has been taken. On July 25, *175

Free access — add to your briefcase to read the full text and ask questions with AI

Related

National Security Counselors v. CIA
969 F.3d 406 (D.C. Circuit, 2020)
Jorge Rojas v. Faa
922 F.3d 907 (Ninth Circuit, 2019)
Elkins v. Federal Aviation Administration
103 F. Supp. 3d 122 (District of Columbia, 2015)
Tereshchuk v. Bureau of Prisons
67 F. Supp. 3d 441 (District of Columbia, 2014)
Regents of the University of California v. Superior Court
222 Cal. App. 4th 383 (California Court of Appeal, 2013)
Sack v. Department of Defense
District of Columbia, 2013
Sikes v. United States
987 F. Supp. 2d 1355 (S.D. Georgia, 2013)
Hodes v. U.S. Department of Treasury
967 F. Supp. 2d 369 (District of Columbia, 2013)
National Security Counselors v. Central Intelligence Agency
960 F. Supp. 2d 101 (District of Columbia, 2013)
Vazquez v. U.S. Department of Justice
District of Columbia, 2012
Judicial Watch, Inc. v. United States Secret Service
803 F. Supp. 2d 51 (District of Columbia, 2011)
Lengerich v. Columbia College
633 F. Supp. 2d 599 (N.D. Illinois, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
445 U.S. 169, 100 S. Ct. 977, 63 L. Ed. 2d 293, 1980 U.S. LEXIS 27, 5 Media L. Rep. (BNA) 2473, Counsel Stack Legal Research, https://law.counselstack.com/opinion/forsham-v-harris-scotus-1980.